Amylin Wins Restraining Order On Lilly Drug Sales

Law360, New York (May 26, 2011, 1:39 PM EDT) -- Amylin Pharmaceuticals Inc. said Thursday that a California federal judge had temporarily blocked Eli Lilly & Co. from using the same sales force to sell Amylin's diabetes treatment and a rival one produced by Boehringer Ingelheim GmbH, in a fight over a marketing agreement.

U.S. District Judge Janis L. Sammartino found that Amylin has sufficiently made a case that Lilly sales representatives tasked with promoting and selling Amylin's Type 2 diabetes treatment exenatide as part of an alliance between the two companies had been exposed to...
To view the full article, register now.